Active	Status	Sponsor type	Region	Phase	Filter
3 Active 3 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LYS-SAF302 / Lysogene, Sarepta Therap
AAVance, NCT03612869 / 2018-000195-15: Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)	Active, not recruiting	2/3	20	Europe, US	LYS-SAF302, AAVrh10-h.SGSH	LYSOGENE	Mucopolysaccharidosis Type IIIA	03/22	03/22
LYS-GM101 / Lysogene
2019-004949-32: LYS-GM101 gene therapy trial in patients with GM1 gangliosidosis	Not yet recruiting	1/2	18	Europe	LYS-GM101, LYS-GM101, Suspension for injection	Lysogene, Lysogene SA	GM1 gangliosidosis, GM1 gangliosidosis, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
NCT04273269 / 2019-004949-32: A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis	Terminated	1/2	5	Europe, US	LYS-GM101	LYSOGENE, Lysogene SA	GM1 Gangliosidosis	05/23	05/23
AAV-Gcase D15 / Lysogene
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LYS-SAF302 / Lysogene, Sarepta Therap
AAVance, NCT03612869 / 2018-000195-15: Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)	Active, not recruiting	2/3	20	Europe, US	LYS-SAF302, AAVrh10-h.SGSH	LYSOGENE	Mucopolysaccharidosis Type IIIA	03/22	03/22
LYS-GM101 / Lysogene
2019-004949-32: LYS-GM101 gene therapy trial in patients with GM1 gangliosidosis	Not yet recruiting	1/2	18	Europe	LYS-GM101, LYS-GM101, Suspension for injection	Lysogene, Lysogene SA	GM1 gangliosidosis, GM1 gangliosidosis, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
NCT04273269 / 2019-004949-32: A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis	Terminated	1/2	5	Europe, US	LYS-GM101	LYSOGENE, Lysogene SA	GM1 Gangliosidosis	05/23	05/23
AAV-Gcase D15 / Lysogene
No trials found